Search This Blog

Sunday, June 1, 2014

New Detailed Phase 3 Data Show Amgen's Novel Investigational Cholesterol-Lowering Medication Evolocumab Significantly Reduced LDL Cholesterol In Patients With A Rare And Serious Genetic Disorder That Causes High Cholesterol

Amgen - Investors - RSS Content

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.